Moderna received Authorization for Emergency Use from FDA of Omicron-targeting bivalent COVID-19 booster vaccine for children
On Oct. 12, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine booster received Health Canada authorization for individuals 12 years of age and older
On Oct. 7, 2022, Pfizer and BioNTech announced that Health Canada had authorized COMIRNATY Original & Omicron BA.4/BA.5…
EMA accepted Moderna’s conditional Marketing Authorization filing for omicron BA.4/BA.5 targeting bivalent COVID-19 vaccine
On Sept. 28, 2022, Moderna announced that the European Medicines Agency (EMA) had accepted a variation for the…
Novavax Nuvaxovid COVID-19 vaccine became available in Israel for individuals aged 12 and older
On Sept. 16, 2022, Novavax announced that the Israel Ministry of Health had granted an import and use…
Moderna completed application to U.S. FDA for EUA of omicron-targeting bivalent Covid-19 booster vaccine
On Aug. 22, 2022, the Food and Drug Administration (FDA) amended the emergency use authorization (EUA) of Moderna…
Medicines and Healthcare Products Regulatory Agency authorized Moderna’s Omicron-containing bivalent booster in the UK
On Aug. 15, 2022, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK…
Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response
On Aug. 9, 2022, Moderna announced an amendment to its agreement with the European Commission (EC) to convert…
HHS announced 66 million doses of Moderna’s variant-specific COVID-19 vaccine booster for potential use in Fall and Winter 2022
On Jul. 29, 2022, the U.S. Department of Health and Human Services (HHS), in collaboration with the U.S….
Pfizer and BioNTech announced clinical trial of next-generation vaccine candidate based on enhanced spike protein design
On Jul. 27, 2022, Pfizer and BioNTech announced that the companies had initiated a randomized, active-controlled, observer-blind, Phase…
EMA Committee for Medicinal Products for Human Use recommended use of the Moderna COVID-19 booster in adolescents (12-17 years)
On Jul. 22, 2022, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
Yale-developed vaccine offers superior protection against Omicron variants
On Jul. 19, 2022, Yale scientists announced they had developed a novel Omicron-specific mRNA vaccine that offers superior…
Australia TGA granted provisional approval for Moderna’s COVID-19 vaccine in children aged six months to five years
On Jul. 18, 2022, Moderna announced that the Therapeutic Goods Administration (TGA) in Australia had granted provisional registration…
Health Canada authorized Moderna’s COVID-19 vaccine in young children (6 months-5 years)
On Jul. 14, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
Moderna’s Omicron-containing bivalent booster candidate, mRNA-1273.214, demonstrated higher neutralizing antibody response
On Jul. 11, 2022, Moderna announced new clinical data on its bivalent Omicron (BA.1) booster candidate, mRNA-1273.214. One…
NIH launched clinical trial of mRNA Nipah virus vaccine
On Jul. 11, 2022, the National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial…
Pfizer and BioNTech submitted a variation to EMA for vaccination of children ages 6 months to less than 5 Years with COMIRNATY
On Jul. 8, 2022, Pfizer and BioNTech announced that the companies had submitted a variation to the European…
BioNTech started construction of first mRNA vaccine manufacturing facility in Africa
On Jun. 23, 2022, BioNTech announced it had reached a milestone in the establishment of scalable mRNA vaccine…
Moderna received FDA authorization for EUA of Its COVID-19 vaccine for children 6 months of age and older
On Jun. 17, 2022, Moderna announced that it had received emergency use authorization from the U.S. Food and…
Roche received FDA EUA for cobas SARS-CoV-2 Duo, the first PCR test to simultaneously detect COVID-19 and measure viral load levels of COVID-19
On Jun. 15, 2022, Roche announced that the US Food and Drug Administration had issued Emergency Use Authorization…
Moderna announced Omicron-containing bivalent booster candidate mRNA-1273.214 demonstrated superior antibody response against Omicron
On Jun. 8, 2022, Moderna announced new clinical data on its Omicron-containing bivalent COVID booster candidate, mRNA-1273.214, containing…
Moderna and the European Commission agreed on amendment to COVID-19 vaccine supply agreement
On Jun. 2, 2022, Moderna announced an agreement with the European Commission (EC) to amend their originally agreed…
Novavax initiated phase 3 trial of its COVID-19 Omicron strain vaccine as a booster
On May 31, 2022, Novavax announced the initiation of its Phase 3 strain change trial to determine if…
Moderna and Takeda announced plans to transfer Marketing Authorization for Spikevax(TM) COVID-19 vaccine in Japan
On May 31, 2022, Moderna and Takeda announced the transfer of the marketing authorization for Moderna’s COVID-19 vaccine…
IAVI and Moderna launched first-in-Africa clinical trial of mRNA HIV vaccine development program
On May 18, 2022, Moderna and the nonprofit scientific research organization IAVI announced that the first participant screenings…
SARS-CoV-2 RNA can persist in stool months after respiratory tract clears virus
On May 18, 2022, SARS-CoV-2, or at least pieces of it, sticks around longer in some infected individuals…
Tabula Sapiens multiple-organ, single-cell transcriptomic atlas of humans published
On May 13, 2022, the Tabula Sapiens Consortium announced it had published a molecular reference atlas for more…
Moderna finalized plan for long-term strategic partnership with the Government of Canada
On Apr. 29, 2022, Moderna announced its plan to build a state-of-the-art mRNA vaccine manufacturing facility in Quebec…
Moderna filed to expand conditional Marketing Authorization for COVID-19 vaccine to include children six months to under six years in the EU
On Apr. 29, 2022, Moderna announced that it had submitted for a variation to the conditional marketing authorization…
Moderna filed for authorization of Its COVID-19 vaccine in young children six months to under six years of age
On Apr. 28, 2022, Moderna announced that it had submitted a request for emergency use authorization (EUA) for…
CureVac and GSK’s bivalent second-generation mRNA accine candidate shown to be highly effective against SARS-CoV-2 variants
On Apr. 21, 2022, CureVac announced preclinical data demonstrating immune responses and protective efficacy of a bivalent second-generation…